Shingrix Vaccine at Chughtai Lab

Shingrix Vaccine at Chughtai Lab

The Shingrix vaccine is a non-live, recombinant subunit vaccine specifically engineered to prevent herpes zoster, commonly known as shingles, and its most debilitating complication, postherpetic neuralgia (PHN). Offered across the extensive diagnostic network of Chughtai Lab in Pakistan, this vaccine represents a major advancement in preventive medicine and geriatric care. Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. After an individual recovers from chickenpox, the virus remains dormant within the sensory nerve ganglia of the central nervous system. Decades later, due to immunosenescence—the natural decline of the immune system with age—or immunosuppression, the virus can reactivate, traveling down the nerve fibers to cause a painful, blistering, dermatomal skin rash.

Unlike older, live-attenuated vaccines, Shingrix is formulated using a recombinant antigen, specifically the varicella-zoster virus glycoprotein E (gE), combined with the proprietary AS01B adjuvant system. This adjuvant is critical because it enhances the body’s immune response, stimulating both humoral (antibody-mediated) and cell-mediated immunity to provide robust, long-lasting protection. Clinical trials and real-world evidence demonstrate that Shingrix is over 90% effective in preventing shingles in adults aged 50 and older, maintaining high efficacy for at least a decade. By offering the Shingrix vaccine, Chughtai Lab provides patients across Pakistan with access to world-class immunization that preserves quality of life, prevents chronic neuropathic pain, and reduces the clinical burden associated with viral reactivation.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation ensures a safe vaccination process and helps manage potential mild side effects. When scheduling your Shingrix vaccine at Chughtai Lab, please observe the following guidelines:

• Medical Consultation: Consult your primary care physician or a specialist at Chughtai Lab to confirm your eligibility, especially if you are immunocompromised, have an active infection, or are undergoing immunosuppressive therapy.
• Review Medical History: Inform the healthcare provider if you have a history of severe allergic reactions (anaphylaxis) to any component of the Shingrix vaccine or any previous vaccine.
• No Fasting Required: There is no need to fast before receiving the Shingrix vaccine. You should eat a balanced meal and stay well-hydrated prior to your appointment.
• Wear Appropriate Clothing: Wear a loose-fitting, short-sleeved shirt or clothing that allows easy access to your upper arm, as the vaccine is administered intramuscularly into the deltoid muscle.
• Manage Active Illnesses: If you are experiencing a moderate or severe acute illness, including a high fever, it is medically advisable to postpone the vaccination until you have fully recovered. Mild illnesses, such as a common cold, are generally not contraindications.
• Active Shingles Episodes: If you currently have an active case of shingles, you must wait until the rash has completely resolved and the skin has healed before receiving the vaccine.

During the Procedure

The administration of the Shingrix vaccine at Chughtai Lab follows strict clinical protocols to ensure patient safety, comfort, and vaccine efficacy:

• Patient Verification and Consent: The nursing staff will verify your identity, review your medical screening form, and obtain informed consent before preparing the vaccine.
• Aseptic Preparation: The healthcare professional will clean the injection site, typically the deltoid muscle of your non-dominant arm, with an antiseptic swab and allow it to air dry.
• Vaccine Reconstitution: Shingrix consists of two vials—a lyophilized antigen component and a liquid adjuvant suspension. The nurse will reconstitute the vaccine immediately before administration under strict aseptic conditions to ensure maximum potency.
• Intramuscular Injection: The vaccine is administered via an intramuscular (IM) injection. The nurse will insert the needle at a 90-degree angle into the deltoid muscle. You may feel a brief pinch or pressure during the injection, which typically takes only a few seconds.
• Post-Vaccination Observation: After the injection, you will be asked to remain in the waiting area for approximately 15 to 30 minutes. This observation period allows healthcare staff to monitor you for any immediate, rare allergic reactions.
• Dosing Schedule Counseling: Before you leave, the staff will schedule your second dose. Shingrix is a two-dose vaccine series, with the second dose administered 2 to 6 months after the first dose. For immunocompromised individuals, the second dose may be given 1 to 2 months after the first.

When is a Shingrix Vaccine Performed?

Primary Prevention of Herpes Zoster in Geriatric Populations

The primary indication for the Shingrix vaccine is the prevention of herpes zoster in adults aged 50 and older. As the immune system undergoes immunosenescence, the specific T-cell immunity that keeps the latent varicella-zoster virus in check declines. This makes older adults highly susceptible to shingles. Physicians strongly recommend Shingrix for this cohort, regardless of whether they remember having chickenpox, as over 99% of adults born before 1980 have been exposed to the virus.

Prophylaxis for Immunocompromised and Immunosuppressed Adults

Adults aged 18 and older who are or will be immunodeficient or immunosuppressed due to disease or therapy are at an elevated risk of shingles and its complications. This includes patients undergoing chemotherapy, solid organ transplant recipients, individuals with HIV, and those on biological therapies or systemic corticosteroids. Because Shingrix is a non-live recombinant vaccine, it is safe for immunocompromised patients, providing crucial protection when live vaccines are strictly contraindicated.

Prevention of Postherpetic Neuralgia and Chronic Neuropathic Pain

Postherpetic neuralgia (PHN) is the most common and debilitating complication of shingles, characterized by severe, burning, or stabbing nerve pain in the area where the rash occurred. PHN can persist for months or even years, severely disrupting sleep, daily activities, and mental health. Physicians prescribe the Shingrix vaccine specifically to prevent this chronic neuropathic pain condition, as clinical data shows the vaccine reduces the risk of PHN by more than 90% in older adults.

Immunization Following Prior Zostavax Vaccination or Shingles Episodes

Patients who have previously received Zostavax (the older, live shingles vaccine) or who have already experienced an episode of shingles are still candidates for Shingrix. The immunity offered by Zostavax wanes significantly over time, and natural immunity following a shingles outbreak does not guarantee protection against future recurrences. Clinicians recommend Shingrix to boost and sustain long-term immunological defense in these individuals once the acute phase of any previous infection has passed.

Reduction of Ophthalmic and Cranial Nerve Complications

When the varicella-zoster virus reactivates in the ophthalmic division of the trigeminal nerve, it causes herpes zoster ophthalmicus (HZO). This condition can lead to corneal scarring, glaucoma, chronic ocular inflammation, and permanent vision loss. Reactivation can also affect other cranial nerves, causing facial paralysis (Ramsay Hunt syndrome) or hearing loss. Immunization with Shingrix is performed to mitigate the risk of these severe, sight-threatening, and neurologically damaging complications.

What Does a Shingrix Vaccine Detect?

While the Shingrix vaccine is a prophylactic immunization rather than a diagnostic test, its administration, clinical evaluation, and immunological response involve several critical parameters, preventive milestones, and physiological indicators. The vaccine addresses, prevents, and helps evaluate the following clinical aspects:

• Induction of Glycoprotein E (gE) Antibodies: Stimulates the production of high titers of antibodies targeting the VZV gE antigen, indicating a robust humoral immune response.
• Activation of gE-Specific CD4+ T-Cells: Promotes cell-mediated immunity, which is the primary defense mechanism preventing latent virus reactivation in the sensory ganglia.
• Prevention of Latent Varicella-Zoster Virus Reactivation: Inhibits the dormant virus from replicating and traveling down the sensory nerves to the skin.
• Mitigation of Postherpetic Neuralgia (PHN) Development: Prevents chronic, debilitating neuropathic pain associated with damaged nerve fibers.
• Prevention of Herpes Zoster Ophthalmicus (HZO): Protects the ophthalmic branch of the trigeminal nerve, preventing ocular complications and vision loss.
• Protection Against Ramsay Hunt Syndrome: Prevents viral reactivation in the geniculate ganglion of the facial nerve, reducing the risk of facial paralysis and otic symptoms.
• Reduction of Acute Dermatomal Pain Intensity: Lowers the severity of acute localized pain if breakthrough shingles occurs.
• Prevention of Secondary Bacterial Skin Infections: Reduces the risk of bacterial superinfections, such as cellulitis or impetigo, in ruptured shingles blisters.
• Avoidance of Post-Herpetic Itch: Prevents chronic, treatment-resistant pruritus that can occur in dermatomes previously affected by shingles.
• Prevention of Motor Neuropathies: Protects against segmental limb weakness or diaphragmatic paralysis caused by viral spread to motor neurons.
• Reduction in Shingles-Related Hospitalization Rates: Lowers the incidence of severe systemic complications requiring inpatient medical care.
• Long-Term Immunological Memory Maintenance: Sustains protective antibody and T-cell levels for at least 10 years post-vaccination.
• Safe Immunization Profile in Immunocompromised Patients: Demonstrates safety and efficacy in patients with compromised immune systems due to its non-live formulation.
• Prevention of Disseminated Herpes Zoster: Prevents the virus from spreading across multiple dermatomes or affecting internal organs, a risk primarily faced by immunocompromised individuals.
• Avoidance of Antiviral-Induced Side Effects: Eliminates the need for high-dose systemic antiviral therapies (e.g., acyclovir, valacyclovir) and their associated renal risks.
• Prevention of Scarring and Post-Inflammatory Hyperpigmentation: Protects skin integrity, preventing permanent dermatomal scarring and discoloration.
• Mitigation of Shingles-Associated Stroke Risk: Reduces the elevated risk of transient ischemic attacks and stroke associated with acute herpes zoster ophthalmicus.
• Protection Against Cranial Nerve Palsies: Prevents extraocular muscle palsies and other cranial neuropathies.
• Maintenance of Quality of Life and Physical Functioning: Preserves physical mobility, mental health, and social functioning in geriatric populations.
• Verification of Complete Two-Dose Immunization Status: Confirms that the patient has completed the full vaccine series required for maximum, long-term efficacy.
• Identification of Vaccine Eligibility and Contraindications: Screens for active shingles, pregnancy, or severe allergies before administration.
• Evaluation of Local Reactogenicity: Monitors transient, expected injection site responses (pain, redness, swelling) as indicators of active immune stimulation.
• Monitoring for Systemic Reactogenicity: Evaluates temporary systemic responses (fatigue, myalgia, headache, low-grade fever) post-vaccination.
• Determination of Appropriate Dosing Intervals: Ensures the second dose is administered within the clinically validated 2-to-6-month window.
• Co-administration Compatibility with Other Adult Vaccines: Allows safe, concurrent administration with other essential vaccines, such as the influenza or pneumococcal vaccines, at separate injection sites.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the administration of the Shingrix vaccine is documented immediately. Upon receiving each dose, patients are provided with an official immunization card that details the vaccine brand, batch number, date of administration, and the scheduled date for the second dose. This physical record is vital for tracking your immunization schedule and may be required for international travel or comprehensive medical records.

In addition to the physical card, Chughtai Lab integrates all vaccination records into its secure digital health ecosystem. Within minutes of administration, your immunization status is updated on the Chughtai Lab Patient Portal and the Chughtai Lab Mobile App. Patients receive an SMS notification with a direct link to download their digital vaccination certificate. This seamless digital access ensures that your health records are securely stored, easily retrievable, and shareable with your primary care physician or specialist whenever required.

Shingrix Vaccine Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Humoral Immune Response (gE Antibodies)	Robust antibody production (seroconversion) indicating protective immunity.	Insufficient antibody response (rare, typically limited to severely immunocompromised individuals).
Cell-Mediated Immunity (CD4+ T-Cells)	High frequency of gE-specific CD4+ T-cells, indicating active cellular defense.	Blunted or absent T-cell response, reducing long-term vaccine efficacy.
Injection Site Reaction	Mild, transient soreness, redness, or swelling at the injection site, resolving within 2 to 3 days.	Severe local reaction, persistent swelling, or secondary bacterial infection (extremely rare).
Systemic Reactogenicity	Mild, temporary fatigue, myalgia, headache, or low-grade fever, resolving within 48 to 72 hours.	Severe systemic symptoms, high fever, or prolonged malaise requiring clinical evaluation.
Dosing Schedule Adherence	Completion of two doses within the recommended 2-to-6-month window (or 1-to-2-month window if immunocompromised).	Delayed second dose or incomplete single-dose status, resulting in suboptimal long-term protection.
Dermatomal Skin Status	Intact skin with no active herpes zoster lesions or unexplained unilateral rashes.	Active shingles rash (vaccination must be postponed until the rash completely resolves).
Neurological Complications	No post-vaccination neuropathic pain, cranial nerve deficits, or localized weakness.	Persistent neuropathic pain (PHN) or cranial nerve palsies despite vaccination (highly reduced risk).
Systemic Allergic Response	No immediate hypersensitivity, urticaria, or respiratory distress post-injection.	Acute allergic reaction, bronchospasm, or anaphylaxis (extremely rare, requiring immediate medical intervention).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Shingrix Vaccine?

• Strict Cold Chain Maintenance: Chughtai Lab utilizes state-of-the-art medical refrigeration systems to ensure the Shingrix vaccine is continuously stored at the optimal temperature of 2°C to 8°C, preserving vaccine potency.
• Qualified and Trained Nursing Staff: Our clinical team consists of highly trained healthcare professionals experienced in aseptic intramuscular injection techniques, ensuring maximum patient safety and comfort.
• Home Vaccination Service: For patients with limited mobility or those who prefer convenience, Chughtai Lab offers professional home vaccination services, bringing world-class healthcare to your doorstep.
• Extensive Network Across Pakistan: With a presence in Lahore, Karachi, Islamabad, and other major cities, accessing the Shingrix vaccine is highly convenient for patients nationwide.
• Digital Health Integration: Your vaccination records, certificates, and dosing reminders are integrated into the Chughtai Lab Mobile App and Patient Portal for instant, lifetime access.
• Premium Patient Care and Safety Protocols: We adhere to international clinical standards, including a dedicated post-vaccination observation period to monitor and ensure patient well-being.
• Authentic Sourcing of Vaccines: Chughtai Lab sources all vaccines directly from authorized international manufacturers and licensed distributors, guaranteeing authentic, high-quality doses.
• Comprehensive Pre-Vaccination Guidance: Our clinical staff provides detailed counseling regarding the dosing schedule, potential side effects, and post-vaccination care to ensure a seamless patient experience.